Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.

Provided in the present disclosure are a milk coagulant, a method for obtaining asclepain of Asclepias Linn. and cysteine protease B of Calotropis R. Br., as well as a method of producing cheese. The milk coagulant includes at least one of the asclepain of Asclepias Linn. and the cysteine protease B of Calotropis R. Br.

Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.

Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.

Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.

Polypeptides, viruses, methods and compositions provided herein are useful for the selective elimination of senescent cells. Method aspects include methods for inducing apoptosis in a senescent cell comprising administering to the cell a polynucleotide, virus, host cell, or pharmaceutical composition described herein. Other methods include expressing a pro-apoptotic gene in a senescent cell comprising administering to the cell the polynucleotide, virus, or pharmaceutical composition as described herein.

Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.

The present invention relates to a cell of the human immune system transduced or transfected with a T cell receptor (TCR) or chimeric antigen receptor (CAR), said cell being further modified to render its MALT1 protease activity constitutive active. The present invention further relates a said cell of the human immune system for use as a medicament. In particular, the present invention relates to said cell for use in adoptive T cell therapy. The invention also comprises a cell of the human immune system transduced or transfected with a T cell receptor (TCR) or chimeric antigen receptor (CAR), and further modified to render its MALT1 protease activity constitutive active for use in a method of treating cancer. The invention also relates to a method for generating a cell of the human immune system, comprising modifying a cell to render MALT1 protease activity constitutive active. The invention further relates to an in vitro method of enhancing the activity of a cell of the human immune system transduced or transfected with a T cell receptor (TCR) or chimeric antigen receptor (CAR), comprising modifying said cell in that MALT1 is rendered constitutive active. The invention also comprises an in vitro use of constitutive active MALT1 for enhancing the activity of a cell transduced or transfected with a T cell receptor (TCR) or chimeric antigen receptor (CAR).

Disclosed are methods of RNA-triggered protein cleavage by the CRISPR Cas7-11-Csx29 complex. A guide RNA specifically hybridizes to a RNA target, and Csx29 cleaves Csx30 when Cas7-11:Csx29 complex binds to the target RNA.

Provided herein are methods for producing site specific PEG modifications to single domain antibodies (e.g., VHHs). Methods for producing site-specifically conjugated bivalent single domain antibodies (e.g., VHHs) are also provided. Methods for labeling (e.g., with a fluorophore or radionuclide) site-specifically PEGylated single domain antibodies and site-specifically conjugated bivalent single domain antibodies are also provided.